Poly Medicure Ltd
NSE:POLYMED

Watchlist Manager
Poly Medicure Ltd Logo
Poly Medicure Ltd
NSE:POLYMED
Watchlist
Price: 1 858.1 INR -2.16% Market Closed
Market Cap: 188.3B INR

Poly Medicure Ltd
Investor Relations

Poly Medicure Ltd., an Indian manufacturer of medical devices, is a compelling narrative of innovation driving tangible impact in healthcare. It embarked on its journey in the late 1990s, seizing on the escalating demand for high-quality medical consumables. The company carved its niche by producing a wide array of disposable medical devices like catheters, infusion therapy systems, and wound closure products, essential in medical facilities worldwide. By establishing a robust manufacturing infrastructure and leveraging economies of scale, Poly Medicure ensures competitive pricing while adhering to global quality standards. A dedication to research and development undergirds their operation, constantly pushing the envelope of modern medical technology.

Revenue streams flow primarily from the sale of these innovative products to hospitals, healthcare institutions, and distributors across more than 100 countries. The company's strategic positioning in the industry is further reinforced by its commitment to sustainability and stringent adherence to regulatory compliance, which helps in sustaining long-term contracts and partnerships. The expansion of its product range and the adoption of automated manufacturing processes don't just meet but often forecast sector demands. By keeping its pulse on global health trends, Poly Medicure ensures not only stable growth in its financial graphs but also cements its authority as a cornerstone entity in the medical supplies marketplace.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Nov 10, 2025
AI Summary
Q2 2026

Revenue Growth: Q2 revenue reached INR 444 crores, up 5.7% YoY and 10.1% QoQ; H1 revenue was INR 847 crores, up 5.3% YoY.

Margin Performance: Gross margin improved to 69.4% in Q2 (up 900 bps YoY); EBITDA margin remained strong at 26.8%, near the top end of the 25–27% guidance.

Acquisitions: Closed acquisitions of Italy-based Citieffe Group and Netherlands-based PendraCare, expected to add about INR 280 crores to annual revenue.

Guidance Update: FY'26 revenue growth guided at 15–16% (down from earlier 20%); domestic growth expected at 28–30%, international at ~10%. H2 revenue guidance between INR 1,080–1,090 crores.

CapEx Plans: CapEx of INR 150 crores spent in H1; INR 250 crores planned for FY'26; similar level expected in FY'27.

Product Pipeline: 20 new products pending CE mark for Europe in 2026; strong focus on expanding in cardiology and critical care.

Cash Position: Ended Q2 with INR 1,109 crores liquidity; post-acquisitions, net cash stands at around INR 800 crores.

Key Financials
Revenue
INR 444 crores
Revenue (H1)
INR 847 crores
Gross Profit
INR 308 crores (Q2), INR 584 crores (H1)
EBITDA
INR 119 crores (Q2), INR 226 crores (H1)
Profit After Tax (PAT)
INR 92 crores (Q2), INR 185 crores (H1)
Gross Margin
69.4% (Q2), 69% (H1)
EBITDA Margin
26.8% (Q2), 26.7% (H1)
Domestic Revenue Growth
up 17–18% YoY (Q2 and H1)
International Revenue Growth
up 9.1% QoQ (Q2); Europe down 9.6% YoY in Q2 but up 5% QoQ
Renal Business Revenue
INR 44 crores (Q2), INR 88 crores (H1)
Liquidity / Net Cash
INR 1,109 crores (Q2 end); around INR 800 crores (post-acquisitions)
CapEx
INR 150 crores (H1 FY'26), INR 250 crores+ planned for FY'26
Working Capital Cycle
Debtor cycle around 80 days; cash conversion cycle 115–120 days
Other Earnings Calls

Management

Mr. Himanshu Baid
CEO, MD & Director
No Bio Available
Mr. Jugal Kishore Baid
Founder & Non Executive Director
No Bio Available
Mr. Naresh Vijayvergiya
Chief Financial Officer
No Bio Available
Mr. Avinash Chandra
Company Secretary & Compliance Officer
No Bio Available
Mr. Rishi Baid B.S.M.E
Joint MD & Executive Director
No Bio Available
Mr. Vishal Baid C.A.
President of Corporate Sales & Marketing
No Bio Available
Mr. P. K. Rastogi C.A.
Assistant Vice President of Finance & Accounts
No Bio Available
Mr. Hemant Bhalla B.Sc.
Senior Vice President of Domestic Sales & Marketing
No Bio Available
Mr. Pankaj Kumar Gupta B.E.
President of R&D
No Bio Available
Mr. Manish Sardana
President of Sales & Marketing - India
No Bio Available

Contacts

Address
HARYANA
Faridabad
Plot No.104-105 & 115-116 , Sector-59, HSIDC Industrial Area, Ballabgarh,
Contacts